← SynDRA
MACITENTAN
SynDRA canonical compound SYN0030071 — structure-anchored drug synonym record
| Clinical phase | Launched |
| Approval status | Approved · Rx |
| Primary target(s) | EDNRB |
| Mechanism of action | Endothelin receptor antagonist |
| Indication | contraceptive |
| Disease area | endocrinology |
All known targets
Mechanisms of action (all sources)
- Endothelin receptor antagonist
- EDNRB ANTAGONIST
- Endothelin receptor, ET-A/ET-B antagonist
- EDNRA ANTAGONIST
- EDNRA MODULATOR
- EDNRB MODULATOR
Drug classes
- Endothelin Receptor Antagonists
- Endothelin Receptor Antagonist
- Endothelin A Receptor Antagonists
- Endothelin B Receptor Antagonists
ATC classes
- C02K · OTHER ANTIHYPERTENSIVES
Cross-references
Synonyms
- opsumit
- ACT-064992
- Macitentan component of opsynvi
- Opsumit
- ACT 064992
- UNII-Z9K9Y9WMVL
- ACT064992
- Z9K9Y9WMVL
- N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide
- N-(5-(4-Bromophenyl)-6-(2-((5-bromo-2-pyrimidinyl)oxy)ethoxy)-4-pyrimidinyl)-N'-propylsulfamide
- CHEBI:76607
- Actelion-1
- Macitentan [USAN:INN]
- macitentanum
- zlchem 5
- Opsumit (TN)
- Macitentan (JAN/USAN)
- (non-labelled)Macitentan-d7
- MLS006011174
- C19H20Br2N6O4S
- SCHEMBL1445625
- GTPL7352
- CHEMBL2103873
- ZLA0005
- EX-A544
- DTXSID50196063
- OPSYNVI COMPONENT MACITENTAN
- RefChem:58979
- C02KX04
- DTXCID60118554
- MFCD17167076
- Macitentan [INN]
- Macitentan (Standard)
- MACITENTAN [MI]
- MACITENTAN [JAN]
- MACITENTAN [USAN]
- MACITENTAN [VANDF]
- A1D5I
Reported adverse events
- Bronchitis
- Headache
- Influenza
- Nasopharyngitis
- Urinary tract infection
- Hepatotoxicity
Look up MACITENTAN in the interactive SynDRA portal →